Clinical Trials Browser

Interventional × AZD 6244 × CNS × Clear all

NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 1 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT06188741 2026-05-29

NF114

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

21 enrolled 12 charts

Neurofibromatosis 1, Neurofibrosarcoma

NCT05101148 2026-05-20

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Phase 1 Active not recruiting

Neurofibromatosis 1

NCT04590235 2026-05-14

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

Astrocytoma, Neurofibromatosis 1

NCT04924608 2026-03-23

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Not yet recruiting

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT06735820 2025-07-03

MEKMDM2

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibrosarcoma

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03213691 2025-02-05

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

21 enrolled 11 charts

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

NCT06763315 2025-01-08

LS-NF1PNs

Phase 2 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06620354 2024-10-01

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

Phase 2 Not yet recruiting

Neurofibromatosis 1

NCT06621082 2024-10-01

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

Phase 2 Not yet recruiting

Neurofibromatosis 1

NCT03326388 2024-04-04

INSPECT

Phase 1/2 Completed

Neurofibromatosis 1, Neurofibroma, Plexiform, Optic Nerve Glioma

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04495127 2023-04-26

Selumetinib Paediatric NF1 Japan Study

Phase 1 Completed

Neurofibromatosis 1

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System